Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents

Jason M. Biegel, Mayura Dhamdhere, Shuang Gao, Chethana P. Gowda, Yuka Imamura Kawasawa, Vladimir S. Spiegelman

Research output: Contribution to journalArticlepeer-review

Abstract

Gain at chromosome 17q21 in neuroblastoma is associated with a poor prognosis, independent of MYCN amplification status. Several potential proto-oncogenes have been identified in this region, one of them—insulin-like growth-factor-2 mRNA binding protein (IGF2BP1)—is expressed at high levels in stage 4 tumors, and associated with overall lower patient survival. Here, we demonstrate that down-regulation of IGF2BP1 activity, either by transcript silencing or chemical inhibition, suppresses neuroblastoma cell growth. Furthermore, the combination of IGF2BP1 inhibition along with commonly used chemotherapeutics that broadly affect DNA synthesis, or cyclin-dependent kinase (CDK) inhibitors that disrupt signal transduction, have a synergistic effect on the suppression of neuroblastoma cell proliferation.

Original languageEnglish (US)
Article number608816
JournalFrontiers in Oncology
Volume11
DOIs
StatePublished - Mar 16 2021

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this